PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
22.68%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
22.99%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
38.32%
Positive EPS growth while GNPX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
38.32%
Positive diluted EPS growth while GNPX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
24.80%
Share count expansion well above GNPX's 15.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.80%
Diluted share count expanding well above GNPX's 15.08%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.87%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
22.60%
Positive FCF growth while GNPX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
19.53%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
73.45%
Positive 3Y OCF/share CAGR while GNPX is negative. John Neff might see a big short-term edge in operational efficiency.
-5088.50%
Negative 10Y net income/share CAGR while GNPX is at 53.52%. Joel Greenblatt sees a major red flag in long-term profit erosion.
66.11%
5Y net income/share CAGR 1.25-1.5x GNPX's 53.52%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
78.36%
3Y net income/share CAGR 1.25-1.5x GNPX's 53.52%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
2877.65%
Equity/share CAGR of 2877.65% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
75.50%
Equity/share CAGR of 75.50% while GNPX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-75.29%
Negative 3Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Negative asset growth while GNPX invests at 829.82%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-36.19%
We have a declining book value while GNPX shows 26216.01%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Our R&D shrinks while GNPX invests at 118.84%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-16.18%
We cut SG&A while GNPX invests at 833.97%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.